- Home
- INSP vs DNTH Comparison
INSP vs DNTH Comparison
Compare INSP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INSP | DNTH |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | INSP | DNTH |
|---|---|---|
| Price | $59.81 | $85.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | $101.07 | ★ $119.60 |
| AVG Volume (30 Days) | ★ 1.4M | 810.8K |
| Earning Date | 05-05-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 179.43 | N/A |
| EPS | ★ 4.89 | N/A |
| Revenue | ★ $82,050,000.00 | $2,036,000.00 |
| Revenue This Year | $8.44 | N/A |
| Revenue Next Year | $8.60 | $58.85 |
| P/E Ratio | $12.25 | ★ N/A |
| Revenue Growth | ★ 62.18 | N/A |
| 52 Week Low | $53.11 | $13.37 |
| 52 Week High | $172.95 | $86.75 |
Technical Indicators
Market Signals| Indicator | INSP | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 36.23 | 83.74 |
| Support Level | $57.57 | $33.94 |
| Resistance Level | $84.26 | N/A |
| Average True Range (ATR) | 4.10 | 4.43 |
| MACD | 0.85 | 3.44 |
| Stochastic Oscillator | 7.32 | 92.50 |
Price Performance
Historical ComparisonAbout INSP Inspire Medical Systems Inc.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.